Across TCGA pan-cancer cohorts, TRAJ24 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRAJ24 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TRAJ24 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAJ24 expression acts as an unfavorable survival marker.
SKCM are the cancer types where TRAJ24 Mutation most reproducibly stratifies survival.